Global biopharmaceutical company AbbVie has received EU approval for its $63 billion bid to acquire its rival Allergan. Approval is conditioned on the divestment of a pipeline Allergan product for the treatment of inflammatory bowel diseases. In announcing the approval today (see here), EU competition chief Margrethe
* = Required Field
*Areas of Interest
MLex content is primarily organized into different areas of interest that cover the main elements of regulatory risk. Please indicate which ones you would like to be included in your Daily Wrap-up alert
MLex Limited and our LexisNexis Legal & Professional group of companies will use your personal information to administer your account and/or provide the products and services that you have requested from us. We may also contact you in your professional capacity with information about our other products, services and events that we believe may be of interest. You can manage your communication preferences via our Preference Center . You can learn more about how we handle your personal data and your rights by reviewing our Privacy Policy .
Natalie McNelis covers mergers for MLex in Brussels. Before joining MLex in 2017, she spent 20 years as an international trade and competition lawyer in law firms including Stibbe and WilmerHale. Natalie has a BA in English from Mount Holyoke College, a JD from Harvard Law School and an LLM in EU law from KU Leuven. She is admitted to the bar in New York.